Objective To determine whether ivermectin treatment can prevent hospitalization in individuals with early COVID-19.

Design A randomized, double-blind, placebo-controlled study was conducted in non-hospitalized individuals with COVID-19 in Argentina.

Based on the following results from this study answer the following questions. Just enter the appropriate value from these results.

Comparative Measures Difference in 2 proportions Odds ratio Relative risk 3 rows compared Nominal Value Phi-coefficient 0.051 Cramer's V 0.051 Value 40.0273l 0.678 0.698 a 95% Confidence Intervals Lower Upper 0.073 0.019 0.349 1 .316 0.378 1 .290 Contingency Tables Contingency Tables Hospitalized Group Yes No Total Ivermectin Observed 16 238 254 Expected 1 9.462 234.538 254.000 % within row 6.3% 93.7% 100.0% % of total 3.1 % 46.8% 49.9% Placebo Observed 23 232 255 Expected 1 9.538 235.462 255.000 % within row 9.0% 91.0% 100.0% % of total 4.5% 45.6% 50.1% Total Observed 39 470 509 Expected 39 470 509 % within row 7.7% 92.3% 100.0% % of total 7.7% 92.3% 100.0% x2 Tests Value df p x2 1 .331 1 0.24862 x2 continuity correction 0.974 1 0.32361 2 test difference in 2 proportions 1.154 0.24862 Likelihood ratio 1.338 1 0.24741 Fisher's exact test 0.31746 N 509 [3]